Regulatory approvals for Crispr Therapeutics' CASGEVY program are increasing, expanding the potential market for the treatment. Government support, including public funds, is likely to be available ...

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

SAN DIEGO--(BUSINESS WIRE)--CRISPR QC, a biotechnology start-up based in San Diego, is pleased to announce a major stride in its ongoing Series A funding round. Known for their CRISPR Analytics ...

Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...

As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.

CRISPR Therapeutics recently presented new preclinical data at the ESGCT 2025 Annual Congress showing its investigational CTX460, using the SyNTase gene editing platform, achieved greater than 90% ...

Vertex Pharmaceuticals plans to sell a gene-editing treatment for sickle-cell disease. A patent on CRISPR could stand in the way. That’s a real nice CRISPR cure you have there. It would be a pity if ...

Cigna Group will eliminate prescription drug rebates in many of its commercial health plans in 2027, a practice that has ...

Nex-z is one of two late-stage projects on the go at Intellia, a specialist in CRISPR gene-editing co-founded by Nobel Prize ...

* Maxcyte will supply systems Co and Casebia as part of license agreement and will receive upfront, milestone, and sales-based payments * Says commercial license builds on an existing research and ...